Company: LGNZZ
Filing Date: 2025-07-02
Form Type: 8-K
Source: 0000886163-25-000042
Chunk: 0

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-07-02
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On July 2, 2025, Ligand Pharmaceuticals Incorporated (“ Ligand”) announced the closing of its previously announced Agreement and Plan of Merger (the “ Merger Agreement”) pursuant to which Ligand’s wholly owned subsidiary, LNHC, Inc. (“ LNHC”) merged with and into CHRO Merger Sub Inc., a wholly owned subsidiary of Channel Therapeutics Corporation (“ Channel”), and became a wholly owned subsidiary of Channel (the “ Transaction”). The combined company will operate under the name Pelthos Therapeutics Inc. (“ Pelthos”), and will commence trading on the NYSE American exchange under the new ticker symbol “ PTHS” on July 2, 2025. Ligand issued a press release announcing the closing of the Merger Agreement and certain other information regarding the Transaction. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

  Exhibit No.      Description                                                                                                
         99.1      Press Release, dated July 2, 2025.                                                                         
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
          104      Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.  

Forward-Looking Statements

This report contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Ligand’s and Pelthos’ current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. Readers are